Haikang Pharmaceutical Group Co., Ltd. (hereinafter referred to as "the Company") held the 39th meeting of its 5th Board of Directors (hereinafter referred to as "the Meeting") on May 29, 2026, via telecommunication voting. The meeting notice was delivered via email on May 25, 2026. The meeting was convened and presided over by Mr. Wang Junmin, the Chairman of the Company. A total of 5 directors were required to attend, and 5 directors attended via telecommunication voting. The notice, convening, and the number of directors participating in the voting all complied with relevant laws, regulations, rules, and the Company's Articles of Association. All directors reviewed and approved the following resolutions by voting:
002653SZSE
Announcement of Resolutions from the 39th Meeting of the 5th Board of Directors
✨ AI Summary
The 39th meeting of the 5th Board of Directors of Haikang Pharmaceutical Group was held on May 29, 2026, via telecommunication. Key decisions included reallocating funds from a previous stock issuance to upgrade production lines at subsidiaries and entering a research collaboration with Eli Lilly. The board approved a loan of 21.93 million and 27.22 million yuan to the subsidiaries for project implementation. Further details will be disclosed in a subsequent shareholder meeting.
Summary generated by AI · Always verify with source document
Full Translation
AI Translation· azure_openai
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.